Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)
Johnson & Johnson (JNJ) posted Cash from Investing Activities of -$1.1 billion for Q2 2026, down 6.73% sequentially from -$1.0 billion in Q1 2026, and up 93.92% YoY from -$572.4 million in Q2 2025.
Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Cash from Investing Activities for 18 years, with the latest figure at -$1.1 billion in Q2 2026.
- Quarterly Cash from Investing Activities rose 93.92% year-over-year to -$1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$7.2 billion (up 68.81% YoY) and the FY2025 annual result came in at -$23.6 billion, down 26.82% from the prior year.
- Cash from Investing Activities declined to -$1.1 billion in Q2 2026 per JNJ's latest filing, from -$1.0 billion in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $3.3 billion in Q2 2023 and troughed at -$18.3 billion in Q2 2025.
- A 5-year average of -$3.5 billion and a median of -$1.3 billion in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 1864.32% in 2022, then jumped 191.22% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$3.6 billion in 2022, then jumped by 66.92% to -$1.2 billion in 2023, then decreased by 9.82% to -$1.3 billion in 2024, then sank by 239.77% to -$4.5 billion in 2025, then surged by 75.25% to -$1.1 billion in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.1 billion, -$1.0 billion, and -$4.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -2.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -569.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.35 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 2.11 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -424.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -1.11 Bn |
| Jun 28, 2026 | -1.11 Bn |
| Mar 29, 2026 | -1.04 Bn |
| Mar 29, 2026 | -1.04 Bn |
| Dec 28, 2025 | -4.49 Bn |
| Dec 28, 2025 | -4.49 Bn |
| Sep 28, 2025 | -542.00 Mn |
| Sep 28, 2025 | -542.00 Mn |
| Jun 29, 2025 | -18.26 Bn |
| Jun 29, 2025 | -18.26 Bn |
| Mar 30, 2025 | -297.00 Mn |
| Mar 30, 2025 | -297.00 Mn |
| Dec 29, 2024 | -1.32 Bn |
| Dec 29, 2024 | -1.32 Bn |
| Sep 29, 2024 | -3.13 Bn |
| Sep 29, 2024 | -3.13 Bn |
| Jun 30, 2024 | -13.69 Bn |
| Jun 30, 2024 | -13.69 Bn |
| Mar 31, 2024 | -464.00 Mn |
| Mar 31, 2024 | -464.00 Mn |